CHANGZHOU PHARMACEUTICAL FACTORY

Overview

CHANGZHOU PHARMACEUTICAL FACTORY is an active pharmaceutical ingredient (API) supplier with 60 active FDA Type II Drug Master Files, covering ABEMACICLIB; ABROCITINIB; AGOMELATINE; APIXABAN; APREMILAST; ATORVASTATIN CALCIUM (TRIHYDRATE).

API / Drug Master Files

CHANGZHOU PHARMACEUTICAL FACTORY holds 60 active (64 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• RESMETIROMActive2025-12-31
• CABOZANTINIBActive2025-12-31
• VIBEGRONActive2025-12-25
• TIRZEPATIDEActive2025-11-28
• SEMAGLUTIDEActive2025-10-29
• DEUCRAVACITINIBActive2025-10-29
• DAROLUTAMIDEActive2025-06-30
• VALSARTAN DISODIUMActive2025-05-30
• ABEMACICLIBActive2025-03-17
• VALSARTANActive2025-01-03
• UPADACITINIB HEMIHYDRATEActive2024-12-26
• BICTEGRAVIR SODIUMActive2024-12-18
• RUXOLITINIB HEMIFUMARATEActive2024-11-19
• DOXYCYCLINE HYCLATE (ROUTE CODE: YDX)Active2024-10-30
• UPADACITINIBActive2024-08-28

Showing 15 of 64 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to CHANGZHOU PHARMACEUTICAL FACTORY in our records. PharmaTek screens the full directory against live FDA enforcement data.